Pidotimod tablet pharmacokinetics and relative bioavailability of.doc

 PAGE \* MERGEFORMAT 29 Pidotimod tablet pharmacokinetics and relative bioavailability of Abstract The use of HPLC, the Italian chemical industry produced by Plymouth Pu Limo oral (400mg / branch) as reference substance, the peptide produced by Institute of Materia Medica Pidotimod tablets (400mg / piece) of Relative bioavailability and pharmacokinetic parameters into line were determined. This study selected 18 healthy male volunteers, using self-control method, a single oral dose of Italian cross-Plymouth Chemical Industry Company and the production of Pu Limo oral peptide drug produced by the Institute of pidotimod tablets 800mg, in the sampling point required to take blood, and blood samples after extracted into HPLC, determination of plasma concentrations. The statistical treatment of their data showed that the half-life pidotimod tablet T1 / 2 of 4.34 ± 3.90h, peak time, Tmax = 2.50 ± 0.34h, the mean residence time MRT of 5.25 ± 0.89h, peak concentration Cmax = 6.20 ± 2.41g/ml, the area under the concentration-time curve AUC of 27.7 ± 8.20h.μg/ml, sample and reference substance of the relative bioavailability F of 100.73 ± 18.91%. Keywords: pharmacokinetics Pidotimod relative bioavailability of HPLC Pidotimod tablets, the main active ingredient is imidacloprid ketone Mott (pidotimod), is a full-regulating the synthesis of immune-stimulating agents, by stimulating and regulating effect of cell-mediated immunity produced. Adult preventive capacity for each 800mg, once a day. The purpose of this study is based on the Italian chemical industry produced by Plymouth Pu Limo oral (400mg / branch) for reference substance validate the use of healthy volunteers, Drug Research Institute polypeptide production Pidotimod tablets (200mg / piece) The relative bioavailability and pharmacokinetic characteristics. An experimental apparatus and test drugs: 1.1 Instrument Shimadzu 6A series of high-performance liquid chromatography